Pacific Biosciences of California, Inc. (PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that industry veteran Christian Henry has been appointed to serve as Chairman of its Board of Directors. As part of its annual review of the leadership structure of Pacific Biosciences, the Board of Directors decided to separate the Chairman and Chief Executive Officer positions in alignment with best practices. Mr. Henry will become Chairman of the Board, effective immediately and Dr. Michael Hunkapiller will continue to serve as President and Chief Executive of the Company, as well as an active member of the board.
Guru establishes three new health care holdings, markets continue falling on coronavirus fears Continue reading...
Q1 2020 Pacific Biosciences of California Inc Earnings Call
Investor confidence is high on Inogen (INGN) stock, thanks to solid prospects.
Masimo (MASI) sees solid growth in key Product segment in Q1.
The Earth BioGenome Project (EBP) and Pacific Biosciences of California, Inc. (PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that PacBio will support the sequencing of ecologically important organisms in the state of California through the EBP. The effort will be centered at the University of California, Davis.
Pacific Biosciences of California, Inc. (PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that it is working with commercial, academic and government research teams that are investigating SARS-CoV-2, the coronavirus responsible for the COVID-19 pandemic. The highly accurate long reads produced by the company’s Single Molecule, Real-Time (SMRT®) Sequencing technology can be used to resolve variants of the virus that exist within one individual or across a population of patients, which is critical to developing and maintaining effective diagnostics, vaccines and medicines.
Pacific Biosciences of California, Inc. (PACB), a leading provider of high-quality sequencing of genomes, transcriptomes, and epigenomes, and inqaba biotec, the leading commercial DNA sequencing service provider in sub-Saharan Africa, today announced the addition of a PacBio Sequel II System to inqaba biotec’s portfolio of genomics services. Based on the well-established Single Molecule, Real-Time (SMRT®) Sequencing technology, the Sequel II System offers highly accurate long reads, with 15x more data compared with the original Sequel System.
Earlier today, we issued a press release outlining the financial results we will be discussing on today's call, a copy of which is available on the Investors section of our website at www.pacb.com or alternatively as furnished on the Form 8-K available on the Securities and Exchange Commission website at www.sec.gov. With me today are Mike Hunkapiller, our Chief Executive Officer; Susan Barnes, our Chief Financial Officer; and Ben Gong, our Vice President of Finance and Treasurer.
MENLO PARK, Calif., May 06, 2020 -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its first quarter ended March 31, 2020. As.
Q4 2019 Pacific Biosciences of California Inc Earnings Call
Pacific Biosciences of California, Inc. (PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced that Michael Phillips has decided to retire from his role as the company’s Senior Vice President of Research and Development as of April 1, 2020. Mr. Phillips has directed the development of PacBio’s technology since joining the company in 2005.
Pacific Biosciences (PACB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Pacific Biosciences (PACB) saw revenue growth in the Service and Other segment in Q1.
Pacific Biosciences' (PACB) new development is likely to boost the company's flagship platform, the Sequel system.
ABIOMED's (ABMD) flagship Impella saw decline in revenues within United States in Q4.
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MENLO PARK, Calif., April 27, 2020 -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) will hold its quarterly conference call to discuss its First Quarter 2020 Financial.
Pacific Biosciences (PACB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Pacific Biosciences of California, Inc. (PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, announced that the jury verdict in the U.S. District Court for the District of Delaware was not overall favorable for Pacific Biosciences, but mixed in terms of its findings. The jury declined to find valid or infringed U.S. Patent No. 9,738,929, also asserted by Pacific Biosciences in the actions. “We are disappointed with today’s verdict, which appears to be internally inconsistent regarding the validity of our patents,” said Dr. Michael W. Hunkapiller, President and Chief Executive Officer of Pacific Biosciences.